Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The Ivy GBM database was then utilized to determine the intratumoral spatial localization of BTK activity by investigating the expression of BTK-related transcription factors (TFs) within tumors.
|
31628288 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Therapeutic targeting of sIgM function via ibrutinib, an inhibitor of Bruton tyrosine kinase (BTK), causes inhibition and tumor cell redistribution into the blood, with significant clinical benefit.
|
30373751 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms.
|
27697038 |
2017 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In conclusion, BCR signaling, activated in the lymph node microenvironment in vivo, appears to promote tumor proliferation and survival and may explain the sensitivity of this lymphoma to BTK inhibitors.
|
27127301 |
2016 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Simultaneous inhibition of BTK and mTOR causes apoptosis both in vitro and in vivo and results in tumor regression in a xenograft model.
|
24970801 |
2014 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.
|
26627823 |
2016 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that the encouraging therapeutic efficacy of Btk inhibitor may be due to both direct cytotoxic effects on malignant B cells and immunomodulatory effects on macrophages present in the tumor microenvironment.
|
28424405 |
2017 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In lymphomas resistant to BTK inhibition, we show that blocking BTK activity enhanced tumor dependencies from alternative oncogenic signals downstream of the BCR, converging on MYC upregulation.
|
29567799 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<i>In vitro</i> studies support the effectiveness of combing PI3Kδ and BTK inhibitors.<b>Experimental Design:</b> As CLL proliferation and survival depends on the microenvironment, we used murine models to assess the efficacy of the BTK inhibitor acalabrutinib combined with the PI3Kδ inhibitor ACP-319 <i>in vivo</i> We compared single-agent with combination therapy in TCL1-192 cell-injected mice, a model of aggressive CLL.<b>Results:</b> We found significantly larger reductions in tumor burden in the peripheral blood and spleen of combination-treated mice.
|
28645939 |
2017 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
By integrating the genomic features of oesophageal tumour cell lines with siRNA and drug screening data, we identified a series of candidate targets in oesophageal cancer, including a sensitivity to inhibition of the kinase BTK in <i>MYC</i> amplified oesophageal tumour cell lines.
|
28830912 |
2018 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, overexpression of BTK in myeloma cells promoted tumor growth in laboratory mice and rendered side population-derived tumors that contained high levels of BTK more sensitive to the selective, second-generation BTK inhibitor, CGI1746, than side population-derived tumors that harbored low levels of BTK.
|
25589346 |
2015 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In immune competent mice, the ibrutinib-sorafenib combination reduced the numbers of BTK+ immune cells in the tumor microenvironment.
|
31582534 |
2020 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
While it has long been considered oncogenic in the context of B cell malignancies, recent data shows that BTK can also act as a tumour suppressor in other cells, as an essential member of the p53 and p73 responses to damage.
|
30337526 |
2018 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was used to detect the Btk expression in kidney from LN patients and tumor surrounding tissues.
|
28612243 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We found that inhibition of BTK leads to suppression of tumor growth, which was mediated via potent suppression of AKT/mTOR, apoptosis, and metabolic stress.
|
30413649 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Significant tumor regression was observed with a combination of PI3Kδ and Bruton's tyrosine kinase inhibitors in the mouse TMD8 xenograft.
|
28178345 |
2017 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.
|
28028621 |
2017 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our results surprisingly show that BTK is expressed in several breast cancer cell lines and tumors.
|
23913792 |
2013 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
|
28265007 |
2017 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
|
22689860 |
2012 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms.
|
27756747 |
2016 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finally, we found that KS99 inhibits the in vivo tumor growth of MM cells through the inhibition of BTK and tubulin.
|
28647392 |
2017 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
|
25805587 |
2015 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
RNA-seq analysis revealed that ARQ531 constrained tumor cell proliferation and survival through Bruton's tyrosine kinase and transcriptional program dysregulation, with proteasome-mediated MYB degradation and depletion of short-lived proteins that are crucial for tumor growth and survival, including ERK, MYC and MCL1.
|
31624110 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.
|
29455639 |
2018 |